152 related articles for article (PubMed ID: 31081489)
1. Cost of antiretroviral treatment for HIV patients in two centres of North India.
Sharma A; Prinja S; Sharma A; Gupta A; Arora SK
Int J STD AIDS; 2019 Jul; 30(8):769-778. PubMed ID: 31081489
[No Abstract] [Full Text] [Related]
2. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
[TBL] [Abstract][Full Text] [Related]
3. Cost implications of HIV retesting for verification in Africa.
Lasry A; Kalou MB; Young PR; Rurangirwa J; Parekh B; Behel S
PLoS One; 2019; 14(7):e0218936. PubMed ID: 31260467
[TBL] [Abstract][Full Text] [Related]
4. [Drugs for antiretroviral therapy. The costs of HAART].
Jablonowski H
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():21. PubMed ID: 19024911
[No Abstract] [Full Text] [Related]
5. Providing antiretroviral therapy for HIV infection.
Steinbrook R
N Engl J Med; 2001 Mar; 344(11):844-6. PubMed ID: 11248164
[No Abstract] [Full Text] [Related]
6. Sustaining treatment costs: who will pay?
Zewdie D; De Cock K; Piot P
AIDS; 2007 Jul; 21 Suppl 4():S1-4. PubMed ID: 17620744
[No Abstract] [Full Text] [Related]
7. Evolution of HIV disease in the third millennium: clinical and related economic issues.
Manfredi R
Int J Antimicrob Agents; 2002 Mar; 19(3):251-3. PubMed ID: 11932152
[No Abstract] [Full Text] [Related]
8. Economic research on HIV prevention, care and treatment: why it is more than ever needed?
Moatti JP; Eboko F
Curr Opin HIV AIDS; 2010 May; 5(3):201-3. PubMed ID: 20539074
[No Abstract] [Full Text] [Related]
9. The changing natural history of HIV disease: before and after the introduction of generic antiretroviral therapy in southern India.
Kumarasamy N; Solomon S; Chaguturu SK; Cecelia AJ; Vallabhaneni S; Flanigan TP; Mayer KH
Clin Infect Dis; 2005 Nov; 41(10):1525-8. PubMed ID: 16231268
[TBL] [Abstract][Full Text] [Related]
10. Trends and economic stress: a challenge to universal access to antiretroviral treatment in India.
Dhamija P; Bansal D; Medhi B
Curr HIV Res; 2009 Jul; 7(4):410-7. PubMed ID: 19601776
[TBL] [Abstract][Full Text] [Related]
11. The economics of effective AIDS treatment in Thailand.
Over M; Revenga A; Masaki E; Peerapatanapokin W; Gold J; Tangcharoensathien V; Thanprasertsuk S
AIDS; 2007 Jul; 21 Suppl 4():S105-16. PubMed ID: 17620745
[TBL] [Abstract][Full Text] [Related]
12. The cost effectiveness of combination antiretroviral therapy for HIV disease.
Freedberg KA; Losina E; Weinstein MC; Paltiel AD; Cohen CJ; Seage GR; Craven DE; Zhang H; Kimmel AD; Goldie SJ
N Engl J Med; 2001 Mar; 344(11):824-31. PubMed ID: 11248160
[TBL] [Abstract][Full Text] [Related]
13. Costing of scaling up HIV/AIDS treatment in Mexico.
Bautista-Arredondo S; Dmytraczenko T; Kombe G; Bertozzi SM
Salud Publica Mex; 2008; 50 Suppl 4():S437-44. PubMed ID: 19082254
[TBL] [Abstract][Full Text] [Related]
14. Costs of eliminating HIV in South Africa have been underestimated.
Wagner B; Blower S
Lancet; 2010 Sep; 376(9745):953-4. PubMed ID: 20851250
[No Abstract] [Full Text] [Related]
15. Simplifying HIV therapeutics, and the global treatment of AIDS.
Laurence J
AIDS Read; 2003 Jan; 13(1):5-6. PubMed ID: 12569889
[No Abstract] [Full Text] [Related]
16. Antiretroviral therapy in children--increased benefit from increased complexity.
Cotton MF
S Afr Med J; 2000 Oct; 90(10):985-8. PubMed ID: 11081099
[No Abstract] [Full Text] [Related]
17. [Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy].
Blasco AJ; Arribas JR; Clotet B; Domingo P; González-García J; López-Bernaldo JC; Llibre JM; Lozano F; Podzamczer D; Santamaría JM; Tuset M; Zamora L; Lázaro P; Gatell JM
Enferm Infecc Microbiol Clin; 2011 Dec; 29(10):721-30. PubMed ID: 22014894
[TBL] [Abstract][Full Text] [Related]
18. Financial and economic costs of scaling up the provision of HAART to HIV-infected health care workers in KwaZulu-Natal.
Deghaye N; Pawinski RA; Desmond C
S Afr Med J; 2006 Feb; 96(2):140-3. PubMed ID: 16532083
[TBL] [Abstract][Full Text] [Related]
19. Recurrent costs of HIV/AIDS-related health services in Rwanda: implications for financing.
Quentin W; König HH; Schmidt JO; Kalk A
Trop Med Int Health; 2008 Oct; 13(10):1245-56. PubMed ID: 18721185
[TBL] [Abstract][Full Text] [Related]
20. Medical resource utilization and cost of HIV-related care in the highly active antiretroviral therapy era at a University Clinic in Sweden.
Ghatnekar O; Hjortsberg C; Gisslén M; Lindbäck S; Löthgren M
Pharmacoeconomics; 2010; 28 Suppl 1():49-57. PubMed ID: 21182343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
